Mathieu Bourgey

Mathieu Bourgey

Auto-generated profile, based on publicly available information

Mathieu Bourgey

McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in GigaScience
Verified
Journal Article
Open access
PDF file
MBMathieu Bourgey
Mathieu Bourgey
RDRola Dali
Rola Dali
RERobert Eveleigh
Robert Eveleigh
KCKuang Chung Chen
Kuang Chung Chen
LLLouis Letourneau
Louis Letourneau
GBGuillaume Bourque
Guillaume Bourque
Background: With the decreasing cost of sequencing and the rapid developments in genomics technologies and protocols, the need for validated bioinformatics software that enables efficient large-scale data processing is growing. Findings: Here we present GenPipes, a flexible Python-based framework that facilitates the development and deployment of multi-step workflows optimized for high-performance computing clusters and the cloud. GenPipes already implements 12 validated and scalable pipelines for various genomics applications, including RNA sequencing, chromatin immunoprecipitation sequencing, DNA sequencing, methylation sequencing, Hi-C, capture Hi-C, metagenomics, and Pacific Biosciences long-read assembly. The software is available under a GPLv3 open source license and is continuously updated to follow recent advances in genomics and bioinformatics. The framework has already been configured on several servers, and a Docker image is also available to facilitate additional installations. Conclusions: GenPipes offers genomics researchers a simple method to analyze different types of data, customizable to their needs and resources, as well as the flexibility to create their own workflows.

17 April 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MDMarie-Gabrielle Duperron
Marie-Gabrielle Duperron
MKMaria J. Knol
Maria J. Knol
QGQuentin Le Grand
Quentin Le Grand
TETavia E. Evans
Tavia E. Evans
AMAniket Mishra
Aniket Mishra
SDStéphanie Debette
Stéphanie Debette
Perivascular space (PVS) burden is an emerging, poorly understood, magnetic resonance imaging marker of cerebral small vessel disease, a leading cause of stroke and dementia. Genome-wide association studies in up to 40,095 participants (18 population-based cohorts, 66.3 ± 8.6 yr, 96.9% European ancestry) revealed 24 genome-wide significant PVS risk loci, mainly in the white matter. These were associated with white matter PVS already in young adults (N = 1,748; 22.1 ± 2.3 yr) and were enriched in early-onset leukodystrophy genes and genes expressed in fetal brain endothelial cells, suggesting early-life mechanisms. In total, 53% of white matter PVS risk loci showed nominally significant associations (27% after multiple-testing correction) in a Japanese population-based cohort (N = 2,862; 68.3 ± 5.3 yr). Mendelian randomization supported causal associations of high blood pressure with basal ganglia and hippocampal PVS, and of basal ganglia PVS and hippocampal PVS with stroke, accounting for blood pressure. Our findings provide insight into the biology of PVS and cerebral small vessel disease, pointing to pathways involving extracellular matrix, membrane transport and developmental processes, and the potential for genetically informed prioritization of drug targets.

1 December 2020 in Cell
Verified
Journal Article
Closed access
RYRui Yang
Rui Yang
FMFederico Mele
Federico Mele
LWLisa Worley
Lisa Worley
DLDavid Langlais
David Langlais
JRJérémie Rosain
Jérémie Rosain
JCJean-Laurent Casanova
Jean-Laurent Casanova

28 June 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MOMasato Ogishi
Masato Ogishi
RYRui Yang
Rui Yang
CACaner Aytekin
Caner Aytekin
DLDavid Langlais
David Langlais
MBMathieu Bourgey
Mathieu Bourgey
JCJean-Laurent Casanova
Jean-Laurent Casanova

3 November 2022 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
GPGundula Povysil
Gundula Povysil
JKJack A. Kosmicki
Jack A. Kosmicki
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
TDTheodore Drivas
Theodore Drivas
JRJ Brent Richards
J Brent Richards
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.

15 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
GPGundula Povysil
Gundula Povysil
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
NSNing Shang
Ning Shang
CWChen Wang
Chen Wang
AKAtlas Khan
Atlas Khan
KKKrzysztof Kiryluk
Krzysztof Kiryluk
A recent report found that rare predicted loss-of-function (pLOF) variants across 13 candidate genes in TLR3- and IRF7-dependent type I IFN pathways explain up to 3.5% of severe COVID-19 cases. We performed whole-exome or whole-genome sequencing of 1,864 COVID-19 cases (713 with severe and 1,151 with mild disease) and 15,033 ancestry-matched population controls across 4 independent COVID-19 biobanks. We tested whether rare pLOF variants in these 13 genes were associated with severe COVID-19. We identified only 1 rare pLOF mutation across these genes among 713 cases with severe COVID-19 and observed no enrichment of pLOFs in severe cases compared to population controls or mild COVID-19 cases. We found no evidence of association of rare LOF variants in the 13 candidate genes with severe COVID-19 outcomes.